ESMO 2021 | DESTINY-Breast03: practice-changing results from ESMO 2021

Nadia Harbeck, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the results of the DESTINY-Breast03 study (NCT03248492), evaluating trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody-drug conjugate versus trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer. T-DXd demonstrated a highly statistically and clinically meaningful improvement in progression-free survival when compared to T-DM1 and represents a paradigm shift in the treatment of HER2+ metastatic breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.